Qidi Medical Health Completes First Round of Strategic Financing with Hangyuan Capital as Exclusive Financial Advisor

VCBeat (WeChat ID: vcbeat) has learned that Tudi Medical Health, a provider of innovative solutions for primary care medical testing, announced that it recently completed its first round of strategic financing following its spin-off from Beijing Yakangbo Biotechnology Co., Ltd. (“Yakangbo Biotech”). Prominent investors participating in this round included PICC Tudi Fund and Wuyuefeng Capital.

Xingyuan Zhitong served as the exclusive financial advisor in the spin-off and first round of strategic financing of Qidi Medical Health.

Tus-Medical Health, formerly the medical laboratory services division of Yakangbo Biology, is now an investment and management platform for third-party medical testing institutions. Centered on the development of regional diagnostic centers, its operations encompass independent clinical laboratory management, biomedical technology R&D and promotion, health big data management, and precision medicine services.

Headquartered in Jiaxing, Zhejiang Province, the company leverages the resource advantages of institutions such as the Zhejiang Tsinghua Yangtze Delta Region Institute and the School of Life Sciences at Tsinghua University to continuously strengthen technological innovation, emphasize industrial integration, and optimize core business operations. As a provider of comprehensive solutions for precision medicine and medical laboratory testing, the company focuses on operating regional medical laboratory centers and managing the clinical laboratories of county- and district-level hospitals. To date, the company has established nine medical laboratories and controlled or equity-participated subsidiaries across China, securing benchmark projects in multiple provinces including East, Central, Northwest, and Southwest China, with business coverage nationwide. Notably, TusMed Health was awarded the “Grassroots Healthcare Innovation Practice Case” by VCBeat in 2019.

Regarding this strategic financing round, Xu Junwu, Founder of Tus Medical Health, stated: “We extend our gratitude to the investors for their support of Tus Medical Health. The implementation of tiered diagnosis and treatment is bringing about transformative changes to the primary care laboratory testing market. Delivering superior medical laboratory services to the grassroots population and empowering the primary care laboratory testing sector represent the original aspiration and mission of every employee at Tus Medical Health. Looking ahead, Tus Medical Health will pursue both speed and quality in its development, contributing to the advancement of China’s medical laboratory testing market.”

As the exclusive financial advisor for this transaction, Cao Shuishui, CEO of Xingyuan Zhitong, stated, “We are highly optimistic about TusMed Health’s resource endowments and the profound industry expertise of its management team led by Xu Junwu. Primary healthcare has become a focal point for capital investment due to the abundant growth opportunities it presents. With its laboratory testing services as a strategic entry point, TusMed Health serves as a highly valuable channel for patient traffic. We believe that, with the support of this round of financing, TusMed Health will undoubtedly achieve even greater progress.”